Puma Biotechnology: Who Are They? What Happened? And, Where Are They Going? (NASDAQ:PBYI) | Seeking Alpha
printmgr file
A New Drug on the Horizon for HER2 Breast Cancer Patients | Avise Analytics
Puma Biotech punts near $300 million on Takeda discard
Puma Biotech (PBYI) Q4 Loss Wider Than Expected, Sales Top
Puma Biotech's (PBYI) Breast Cancer Drug Nerlynx Aids Growth
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
PUMA_BIOTECHNOLOGY
Puma Biotech (PBYI) Up More Than 95% in 3 Months: Here's Why
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech (PBYI) Q4 Loss Wider Than Expected, Sales Top | Nasdaq
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology, Inc.
Puma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Fall Y/Y
Puma Biotechnology: Waiting For Commercial Numbers To Catch Up To Clinical Data (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Why Puma Biotechnology's Shares Jumped 20% on Monday | The Motley Fool
Puma Biotech (PBYI) Q3 Earnings Top, Nerlynx Sales View Up
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
ADAPTING
Puma Biotechnology
Neratinib Chapter
Jon Mead - Vice President of FP&A - Puma Biotechnology, Inc. | LinkedIn
Workable Strategic Report on Breast Cancer Therapeutics Drugs
Product Pipeline
